Parkinson’s disease : current treatments and the possible use of Cannabis by Azzopardi, Joseph Ignatius & Ferry, Peter
Malta Medical Journal, 32 (1): Pages (2020) 
http://mmsjournals.org/index.php/mmj/article/view/144 
 
The Editorial Board retains the copyright of all material published in the Malta Medical Journal. Any reprint in any form of any part will 
require permission from the Editorial Board. Material submitted to the Editorial Board will not be returned, unless specifically requested. 
Malta Medical Journal     Volume 32 Issue 01 2020           
REVIEW ARTICLE
Parkinson's Disease - Current Treatments and the 
Possible Use of Cannabis  
Joseph Ignatius Azzopardi, Peter Ferry 
Parkinson’s disease is a progressive neurodegenerative movement 
disorder common in old age. The current prevalence of this condition 
in the western world is estimated to be 0.3% of the entire population, 
and this value is expected to increase due to the ageing world 
population.  
 
Although there is no cure for Parkinson’s disease, many therapies 
aimed to relieve patients from its motor and/or non-motor 
symptoms exist, both pharmacological and surgical such as levodopa 
and deep brain stimulation, respectively. However, these therapies 
have their own problems and disadvantages, for instance levodopa-
induced dyskinesia.  
 
As there is currently a movement bringing about the legalisation of 
cannabis use for medicinal purposes, many studies are being carried 
out to discover if cannabis or cannabinoids can be used as a 
treatment modality, hopefully with less side effects than current 
treatments, to alleviate patients suffering from Parkinson’s disease 
from their symptoms.  
 
In this paper we seek to review the current treatment options 
available to these patients and what the latest studies in 
cannabinoids have determined with regards to their use in 
Parkinson’s disease.  
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PARKINSON’S DISEASE …  WHAT’S IN A NAME? 
Parkinson’s disease (PD) is a progressive 
neurodegenerative movement disorder – it is 
the commonest movement disorder and the 
second commonest neurodegenerative 
disorder following Alzheimer disease, 
occurring mostly in old age. The current 
prevalence of PD in the western world is 
estimated to be 0.3% of the entire population, 
rising to 1% in people aged over 60, with the 
prevalence expected to increase as the size of 
the geriatric population in many countries is on 
the rise.1–4 
The disease was described for the first time in 
1817 by Dr James Parkinson calling it a 
“shaking palsy”.5 While the disease is mostly 
characterised by its motor symptoms such as 
bradykinesia, gait disturbance, rigidity and a 
resting tremor; non-motor symptoms such as 
depression, apathy, anxiety, insomnia, 
orthostatic hypotension, erectile dysfunction, 
constipation and fatigue amongst others can 
also occur.6 
Pathologically, PD is characterised by the loss 
of the dopaminergic neurons found in the 
substantia nigra pars compacta and the 
presence of Lewy bodies and Lewy neurites in 
the remaining neurons. Onset of symptoms 
occurs when approximately 80% of the 
dopaminergic neurons in the substantia nigra 
are lost.7 
 
A  SHORT HISTORY OF MEDICAL CANNABIS  
The medicinal use of cannabis (Cannabis sativa) 
spans thousands of years, with the earliest 
written evidence being found in the world’s 
first pharmacopeia – pen-ts’ao ching – which 
was based on oral traditions passed from one 
generation to another since 2,7000 B.C.8-9 
The introduction of cannabis as a form of 
medication in Western medicine was made 
possible by the work of Dr William Brooke 
O’Shaughnessy, an Irish physician. The use of 
cannabis for medical purposes then became 
widely disseminated by the 19th century.9 
In the 1930’s and 1940’s however, the medical 
use of cannabis quickly fell out of use due to 
fears of the socially deviant behaviours which 
were attributed to the recreational use of this 
drug, leading to many countries banning the 
cannabis from its use in medicine. Things have 
recently started to change, with many 
countries, including Cyprus, Malta and the 
United Kingdom starting to overturn their ban 
on the use of cannabis in medicine.9–12 
Despite the recent legalisation of marijuana, a 
recent survey has showed that many experts in 
the field of PD still have a lack of knowledge in 
how cannabis can be used in the treatment of 
PD, probably because of the lack of high-
quality data and education about the effects of 
cannabis on this disorder.13 The aim of this 
review is to bring the latest information about 
cannabis use in the treatment of Parkinson’s 
disease in one document to facilitate the 
acquirement of knowledge about this subject. 
 
CURRENT MODALITIES OF TREATMENT OF PD 
AND THEIR CAVEATS 
No cure for PD has yet been found, therefore 
all current treatments are strictly 
symptomatic; they can neither halt nor reverse 
the progressive nature of this disease. The 
current drugs marketed for the treatment of 
PD symptoms work either by increasing the 
dopamine levels in the brain or by mimicking 
the effects of dopamine.7 
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Levodopa 
The gold-standard treatment for PD is 
levodopa, a dopamine precursor which it 
breaks down into dopamine once in the brain. 
To prevent its breakdown in the periphery, 
levodopa is co-administered with a DOPA-
decarboxylase inhibitor such as carbidopa or 
benserazide. The use of levodopa is not 
without its problems; for instance, it is 
ineffective for the control of non-motor 
symptoms of PD. Furthermore, ‘on-off’ and 
‘end-of-dose’ motor fluctuations frequently 
occur after several years of treatment with this 
drug.7 Controversy on whether levodopa is 
actually toxic to dopaminergic neurons also 
exists.14 
 
COMT Inhibitors 
Catechol-O-methyl transferase (COMT) 
inhibitors such as entacapone are commonly 
used as adjuncts to co-beneldopa and co-
careldopa such as in Stalevo to overcome 
motor fluctuations.15 
Common side effects of entacapone include 
constipation, orthostatic hypotension (which 
could theoretically increase the risk of 
fractures from falling) and confusion. Caution 
must be taken when entacapone is prescribed 
to individuals with a history of ischaemic heart 
disease as this drug is known to increase its 
risk.16-17 
Tolcapone, another COMT inhibitor effective 
in the control of motor fluctuations has been 
reported to have caused four cases of acute 
hepatotoxicity resulting in three fatalities. As a 
result, the use of this drug has been either 
completely withdrawn or severely restricted in 
many countries.18–21 
 
 
Dopamine Receptor Agonists 
Dopamine receptor agonists (DRAs) are 
another modality of treatment of PD, whereby 
they stimulate dopamine receptors by 
mimicking the dopamine molecule. DRAs can 
be used as adjuncts to levodopa in the 
advanced stages of PD or as monotherapy 
during the initial stages of PD to delay the 
need for levodopa.7,22 
DRAs can be divided into two main classes; the 
ergot derivatives such as pergolide, and the 
non-ergot derivatives such as pramipexole and 
ropinirole. The latter are preferred over the 
former because of the risks of retroperitoneal 
fibrosis, pleuropulmonary fibrosis and fibrotic 
heart valvular disease associated with their 
use.23-24 
The non-ergot derivates are not without their 
problems as they are associated with 
compulsive gambling and hypersexual 
behaviour.25 
 
MAO-B Inhibitors 
Monoamine oxidase B (MAO-B) inhibitors such 
as rasagiline inhibit the metabolism of 
dopamine such that they enhance the effect of 
levodopa if they are used in conjunction.7 
Patients on MOA-B inhibitors must be advised 
to limit their intake of tyramine as a potentially 
lethal hypertensive crisis can result when large 
amounts of this amino acid are consumed.26 
 
Amantadine 
Amantadine, an aminoadamantane originally 
used as an antiviral agent, is a non-competitive 
NMDA receptor antagonist which is now being 
used to treat early PD symptoms, and 
increasingly more as a treatment for 
dyskinesias caused by levodopa in those with 
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advanced PD.27–29 However, several clinical 
studies have shown that treating PD patients 
with amantadine prior to initiating levodopa 
treatment is ineffective in delaying or reducing 
the onset of levodopa-induced dyskinesias.30,31 
Some clinical trials have also shown a relation 
between amantadine treatment and a 
reduction in the previously mentioned 
‘impulse control disorders’ found in PD 
patients.32,33 The author of one of these 
studies hypothesise that this reduction could 
be due to the anti-glutamatergic properties of 
amantadine.33 While the results from these 
studies are encouraging, further clinical trials, 
which are larger in size, are needed to shed 
more light on the possible use of this drug as a 
treatment modality for impulse control 
disorders in PD patients. 
Unfortunately, both the use and the 
withdrawal of amantadine are marred by a 
range of adverse effects, which might make 
the clinician cautious about using this drug as 
the risks might easily outweigh any benefit 
that treatment with this drug may convey. 
Side effects of amantadine treatment on the 
vision and eyes have been reported widely, 
including oculogyric crises, visual loss, 
mydriasis, corneal oedema and hallucinations 
amongst others.34–36  
Some papers also report some interesting 
cases where the use or withdrawal of 
amantadine in PD was associated with adverse 
effects not usually attributed to it, such as the 
development of patulous Eustachian tubes 
(PET),37 dropped head syndrome,38 severe 
psychosis,39 right ventricular outflow tract 
tachycardia40 and syndrome of inappropriate 
antidiuretic hormone secretion.41 
 
 
Anticholinergics 
Anticholinergic agents, in the form of alkaloids 
derived from the Solanaceae family,42 are the 
oldest medication in use for the treatment of 
PD after their antiparkinsonian effects were 
first described by Leopold Ordenstein in 
1868.43 Since then, anticholinergic agents 
remained the only pharmacological treatment 
option for PD for almost a century until the 
introduction of levodopa and amantadine in 
the 1960’s.44 
Although the use of anticholinergics for the 
treatment of motor symptoms in PD has 
declined due to the increasing use of levodopa 
and other drugs,45 they are still the first-line 
treatment for bladder dysfunction, the 
commonest autonomic disorder in PD which 
also tends to be non-responsive to levodopa.46-
47 
As anticholinergic drugs are often prescribed 
for the treatment of sialorrhea in patients with 
cerebral palsy, sublingual atropine has  been 
investigated for potential use in treating 
sialorrhea in PD patients.48,49 While sublingual 
atropine did result in an amelioration in 
sialorrhea, 3 out of the 7 study subjects 
experienced adverse effects, mainly of 
cognitive nature.49  Due to such results, the use 
of atropine in the management of sialorrhea in 
PD patients is only recommended by the NICE 
guidelines if the “risk of cognitive adverse 
effects is thought to be minimal”.50-51  
In 2018,  a case report was published where a 
75-year-old gentleman with a known case of 
PD developed psychosis and delirium 
following the commencement of sublingual 
atropine.50 
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Indeed, although studies have shown 
anticholinergic agents to be more effective in 
treating motor symptoms in PD than placebo, 
their adverse effects, especially on cognitive 
function in PD patients - who due to the 
cholinergic dysfunction associated with their 
disease makes them more prone to 
anticholinergic effects – greatly limit their 
use.17,52 
 
Deep Brain Stimulation 
Deep brain stimulation of the subthalamic 
nucleus is the preferred surgical treatment for 
advanced PD, especially in those who respond 
to pharmacological treatment but have motor 
fluctuations. While in general, the quality of 
life of the patients undergoing this surgery 
increases as the symptoms are improved, side 
effects and complications do exist. Pneumonia 
(amongst other infections) and intracranial 
haemorrhage are the commonest 
complications associated with the surgical 
procedure itself, albeit the frequency of such 
complications is relatively low, occurring at a 
rate of 0.6% and 2.2%, respectively. 
Furthermore, the mortality rate and the rate of 
permanent surgical morbidity were found to 
be 0.4% and 1%, respectively.53 Adverse 
effects to the stimulation are possible but are 
often reversible and can be alleviated by 
adjusting the kind of stimulation.54 In most 
cases, the incidence of complications can be 
reduced or prevented by carefully selecting 
the patients for surgery which are the most 
likely to benefit from such a procedure while 
having a low risk profile vis-à-vis surgical 
complications.55 
 
 
CANNABIS …  THE FUTURE OF PD TREATMENT? 
A 2017 report on the health benefits of 
cannabis “The Health Effects of Cannabis and 
Cannabinoids: The Current State of Evidence 
and Recommendations for Research” carried 
out by the “National Academies of Sciences, 
Engineering and Medicine” concluded that 
while there is conclusive or substantial 
evidence that cannabis/cannabinoids are 
effective for the treatment of chronic pain in 
adults and as antiemetics to name a few, there 
is insufficient evidence to prove or disclaim the 
effectiveness of cannabis or cannabinoids in 
the treatment of PD.56 In this paper, we will be 
reviewing the current state of evidence that 
exists for and against the use of this drug for 
the treatment of PD and what led the 
“National Academies of Science, Engineering 
and Medicine” to come to this conclusion. 
Cannabis contains over 100 different 
phytocannabinoids – compounds occuring in 
plants that interact the endocannabinoid 
system. The main phytocannabinoids 
responsible for the therapeutic effects of 
cannabis are ∆9-tetrahydrocannabidiol (THC) 
which is the primary psychoactive component 
of cannabis and cannabidiol (CBD), a non-
psychoactive compound that has been shown 
to possess anti-inflammatory, anti-psychotic, 
neuroprotective and analgesic properties.57,58 
These compounds interact with the 
endocannabinoid system – a system composed 
of the cannabinoid type 1 and 2 receptors (CB1 
and CB2 respectively), the endogenous ligands 
that bind to these receptors, known as 
endocannabinoids, and the proteins that are 
responsible for the syntheses, reuptake and 
degradation of these ligands.59 
While CB1 receptors are expressed both in the 
central nervous system and the periphery, they 
are most abundant in the former, especially in 
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the structures that are related to movement 
i.e. basal ganglia, prefrontal cortex, 
hippocampus and cerebellum.60 Indeed, CB1 
receptors are the most widely distributed G-
protein-coupled receptor in the CNS.61 
Several studies have reported an upregulation 
of CB1 receptors in the basal ganglia as a 
response to the depletion in dopamine 
typically seen in PD; highlighting the possibility 
of employing cannabinoids as therapeutic 
agents in the treatment of the motor 
symptoms associated with PD.62 
Basal ganglia are the subcortical nuclei which, 
in connection with the brainstem, thalamus 
and motor cortex, they modulate voluntary 
motor movements through two pathways: (1) 
the direct pathway which is mediated by D1 
receptors and promotes movement, and (2) 
the indirect pathway which is mediated by D2 
receptors which inhibits movement.63–65 
Normally, these two pathways are in balance 
with each other; this balance is lost in PD as the 
depletion of dopamine in the striatum causes 
inhibition of the direct pathway and activation 
of the indirect pathway. This loss in balance 
results in an over-inhibition of the thalamus 
leading to an excessive inhibition of motor 
symptoms which in turn results in parkinsonian 
motor features.63–66 
Via the CB1 receptors located at the level of 
the presynaptic region of the glutamatergic 
terminal, cannabinoids can reduce the 
glutamatergic overactivity that results from 
the change in the balance between the direct 
and indirect pathways.67 
 CB2 receptors levels are usually very low in 
the healthy brain but increase in cases of injury 
or inflammation. They occur mostly in the 
periphery such as in the thymus and spleen.67–
69 
 
Pertwee argues that CBD antagonises the 
action of CB1 and CB2 receptor agonists, acting 
as an inverse agonist of these receptors 70. 
Some of the latest studies have suggested that 
CBD acts as a non-competitive negative 
allosteric modulator of both CB1 and CB2 
receptors.71,72 Some of the effects of CBD 
seem to result from the increase in the 
anandamide levels induced by the 
aforementioned cannabinoid as it inhibits its 
enzymatic hydrolysis and uptake.73 
Mitochondrial dysfunctions, such as those due 
to the alterations in mitochondrial DNA, 
bioenergetic defects, reactive oxygen species 
generation and dysfunctional calcium 
homeostasis have all been associated with the 
mechanisms underlying the neuronal death in 
PD.74 Interestingly, studies have found that 
CBD acts on the mitochondria by increasing 
the activity of the mitochondrial complexes I, 
II, II-III and IV in rats. CBD has also been 
reported to reverse the epigenetic 
modifications of mitochondrial DNA induced 
by iron overload in rats. Iron overload induces 
pathological changes that resemble 
neurodegenerative disorders like PD.75,76 
As already mentioned, levodopa, while 
effective in treating the motor symptoms of 
PD, it is ineffective in the treatment of non-
motor symptoms, which can have as much of 
devastating effects on the patient as much as 
the motor symptoms. A 2009 study found that 
treating PD patients with CBD for 4 weeks 
resulted in a decrease in the psychotic 
symptoms without affecting the motor 
function or causing adverse effects.77 
A randomised, double-blind placebo-
controlled, crossover study involving five 
participants showed a significant reduction in 
levodopa-induced dyskinesia and in the 
symptoms associated with rapid eye 
movement sleep behaviour disorder in those 
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treated with nabilone (a synthetic cannabinoid 
similar to THC) when compared with those 
taking the placebo.78  
Another 2014 study by Chagas et al. also that 
treating PD patients with CBD results in an 
improvement in their quality of life, even if 
their symptoms are not ameliorated. This 
finding has been suggested that it might be 
due to the anxiolytic, antipsychotic and 
antidepressant effects that they exert.79 The 
same finding has been reported in another 
study in which participants treated with 75 mg 
or 300 mg daily doses of CBD failed to report 
any change in PD symptoms as assessed using 
the Unified Parkinson's Disease Rating Scale 
(UPDRS) but they did report an improvement 
in the quality of life as assessed using the 
Parkinson's Disease Questionnaire (PDQ-39).80 
In a 2015 study based on self-administered 
surveys found that more than 70% of PD 
patients that made use of cannabis that were 
surveyed reported improvement in mood and 
sleep.81 
Although these studies herald an opportunity 
for the treatment of PD with levodopa in 
conjunction with CBD to control both the 
motor and non-motor symptoms, they were 
unfortunately underpowered and therefore 
the samples are not representative of the 
general PD population. Furthermore, the study 
carried out by Lotan et al. was open-label, 
increasing the risk of bias in the results 
obtained one must therefore be cautious 
when analysing such results. 
Other studies have failed to show optimistic 
results regarding the use of cannabis in 
treating PD. For instance, in studies carried out 
by Carroll et al. and Mesnage et al. involving 
seventeen and eight participants respectively 
failed to show any significant improvement in 
motor or non-motor symptoms when treated 
with Cannador and Rimonabant, 
respectively.82-83 
While back in 1999, the Institute of Medicine 
declared the short-term use of cannabinoids to 
be safe, little has been done to determine the 
safety of cannabinoids in the long-term use.84 
If the cannabinoids are administered by 
smoking the cannabis plant, certain side 
effects related to the act of smoking can be 
expected, such as chronic bronchitis or other 
respiratory diseases.85 
While many studies have shown that CBD has 
an antipsychotic effect,84 Udow et al. argue 
that since patients with PD have an inherent 
risk of psychosis, they are more likely of 
developing psychosis if they are subjected to 
cannabinoids. Udow et al. presented a case 
study where a 70-year old woman with a 12-
year history of PD developed an exacerbation 
of psychosis following the ingestion of 
nabilone.86 
This difference in the literature is due to the 
generalisation made by Udow et al. where they 
attribute the occurrence of psychosis with 
cannabinoids in general. In their same paper, 
they specify that the 70-year old lady had 
exacerbation following the ingestion of 
nabilone – a synthetic chemical that mimics 
THC, the psychoactive agent in cannabis which 
studies have found to cause psychotic 
symptoms. On the other hand, the 
antipsychotic effect has only been reported in 
CBD, a non-psychoactive agent. Hence, one 
must not make the mistake of generalising all 
the cannabinoids together, as there can be 
major differences pharmacological action 
between one cannabidiol and another.  
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CONCLUSION 
In agreement with the 2017 report by the 
“National Academies of Science, Engineering 
and Medicine” the current evidence in favour 
of cannabinoids for the treatment of PD is of 
low quality and inconclusive. Further studies 
and clinical trials involving larger sample sizes 
and better methods are needed to reach a 
conclusion on whether cannabidiols are the 
future of PD treatment or not. 
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